For the quarter ending 2026-03-31, MBX has $452,701K in assets. $14,945K in debts. $45,214K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 45,214 | 75,289 | 223,125 | 39,781 |
| Marketable securities | 394,763 | 298,416 | 168,548 | 185,125 |
| Prepaid expenses and other current assets | 8,559 | 7,834 | 5,829 | 4,284 |
| Total current assets | 448,536 | 381,539 | 397,502 | 229,190 |
| Total property and equipment | 3,867 | 3,405 | 2,614 | - |
| Less accumulated depreciation | 734 | 670 | 610 | - |
| Property and equipment, net | 3,133 | 2,735 | 2,004 | 1,730 |
| Right-of-use assets | 453 | 487 | 520 | 551 |
| Other assets | 579 | 383 | 50 | 50 |
| Total assets | 452,701 | 385,144 | 400,076 | 231,522 |
| Accounts payable | 6,974 | 2,977 | 3,768 | 5,764 |
| Accrued expenses | 7,415 | 12,346 | 8,140 | 5,854 |
| Operating lease liability, current | 178 | 172 | 154 | 138 |
| Total current liabilities | 14,567 | 15,495 | 12,062 | 11,756 |
| Share repurchase liability | 1 | 2 | 7 | 15 |
| Operating lease liability, net of current | 377 | 424 | 469 | 512 |
| Total liabilities | 14,945 | 15,921 | 12,538 | 12,283 |
| Common stock, 0.0001 par value, 500,000,000 shares authorized and 47,570,464 issued and outstanding as of march 31, 2026 and 500,000,000 shares authorized and 44,927,953 issued and outstanding as of december 31, 2025 | 6 | 6 | 6 | 5 |
| Additional paid-in-capital | 686,349 | 593,407 | 589,792 | 400,019 |
| Accumulated deficit | -247,993 | -224,476 | -202,414 | -180,796 |
| Accumulated other comprehensive (loss) income | -606 | 286 | 154 | 11 |
| Total stockholders' equity | 437,756 | 369,223 | 387,538 | 219,239 |
| Total liabilities and stockholders' equity | 452,701 | 385,144 | 400,076 | 231,522 |
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)